BIOVAXYS TECHNOLOGY CORP - BVAXF STOCK NEWS

Welcome to our dedicated page for BIOVAXYS TECHNOLOGY news (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on BIOVAXYS TECHNOLOGY stock.

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and its HapTenix© 'neoantigen' tumor cell construct platform. They focus on treating cancers, infectious diseases, antigen desensitization, and other immunological fields. The company has a range of products in their clinical stage pipeline, including maveropepimut-S and BVX-0918, which target different types of cancers like Diffuse Large B Cell Lymphoma (DLBCL) and ovarian cancer. BioVaxys also capitalizes on its tumor immunology expertise to identify new targetable tumor antigens using predictive algorithms and other technologies.

02/08/2022 01:02 AM

News

BIOVAXYS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-12.01%

Tags

11/17/2021 08:00 AM

News

BioVaxys Co-Founder and Chief Medical Officer David Berd, MD, to Present at World Vaccine & Immunotherapy Congress West Coast 2021

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.48%

Tags

11/09/2021 08:00 AM

News

BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.38%

Tags

10/08/2021 03:00 AM

News

BioVaxys Announces BVX-0320 Poster Presentation at ISIRV-WHO Virtual Conference

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.7%

Tags

09/28/2021 08:00 AM

News

BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-8.2%

Tags

09/20/2021 12:02 PM

News

BioVaxys Engages Life Sciences Public Relations and Market Communications Firm 6 Degrees

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-7.77%

Tags

09/20/2021 08:00 AM

News

BioVaxys ENGAGES life sciENCES Public relations and market communications firm 6 degrees

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-7.77%

Tags

09/17/2021 03:00 AM

News

BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

26.07%

Tags

09/14/2021 03:00 AM

News

BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

29.87%

Tags

09/07/2021 08:00 AM

News

Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.96%

Tags

FAQ

What is the current stock price of BIOVAXYS TECHNOLOGY (BVAXF)?

The current stock price of BIOVAXYS TECHNOLOGY (BVAXF) is $0.0483 as of September 6, 2024.

What is the market cap of BIOVAXYS TECHNOLOGY (BVAXF)?

The market cap of BIOVAXYS TECHNOLOGY (BVAXF) is approximately 11.3M.

What is BioVaxys Technology Corp focused on?

BioVaxys Technology Corp is dedicated to improving patient lives with immunotherapies for cancers, infectious diseases, antigen desensitization, and other immunological fields.

What are some products in BioVaxys' clinical stage pipeline?

BioVaxys has products like maveropepimut-S and BVX-0918 in its clinical stage pipeline, targeting cancers such as Diffuse Large B Cell Lymphoma (DLBCL) and ovarian cancer.